Category:

Sexual Health

Description / Intended Use:

A bremelanotide/PT-141 nasal peptide product positioned for sexual desire and arousal support. Bremelanotide is a melanocortin receptor agonist; the FDA-approved medication form is a subcutaneous injection for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Intranasal use and exposure are formulation-specific and should be clinician-directed.

Common clinical-style protocols

• Commonly used on an as-needed basis before anticipated intimacy rather than as a routine daily product.
• Amount per use should follow the prescriber label; avoid repeat dosing beyond prescribed limits.
• Timing is commonly 30-120 minutes before sexual activity, based on response and tolerability.

Typical target exposure

Short-term melanocortin/sexual-response exposure around anticipated activity.

Common practical schedule

Use only on planned intimacy days; avoid stacking with alcohol or other vasodilating sexual-health drugs unless cleared by the prescriber.

Typical cycle length

Intermittent as-needed use; reassess after several uses or 4-8 weeks.

Common side effects

Nausea, flushing, headache, nasal irritation, dizziness, increased blood pressure, darkening of gums/skin areas, injection-like PT-141 class effects. Avoid with uncontrolled hypertension unless clinician-approved.